Innovus Pharma orders 220,000 units of FlutiCare for product launch

FlutiCare, an over-the-counter fluticasone propionate nasal spray, treats patients with allergies.
FlutiCare, an over-the-counter fluticasone propionate nasal spray, treats patients with allergies. | Contributed image

Innovus Pharmaceuticals has ordered 220,000 units of FlutiCare, putting the drug on pace to meet its planned launch for the fourth quarter of 2017.

FlutiCare, an over-the-counter (OTC) fluticasone propionate nasal spray, treats patients with allergic rhinitis, more commonly referred to as “allergies.”

“We are very excited about the upcoming commercial launch of our FlutiCare product in the United States,” Dr. Bassam Damaj, president and CEO of Innovus Pharma, said in a statement. “We have ordered our initial commercial batch of the product, are finalizing our on-line, Beyond Human, retail and wholesale sales and marketing efforts and are gearing up for a successful launch of FlutiCare in the fourth quarter of this year. We believe that the launch of FlutiCare should have an important impact on the gross revenues of the company.”

Innovus Pharma, headquartered in San Diego, California, develops and commercializes OTC products that target respiratory diseases with the goal of improving health and vitality.

Want to get notified whenever we write about Innovus Pharmaceuticals, Inc. ?
Next time we write about Innovus Pharmaceuticals, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Innovus Pharmaceuticals, Inc. 9171 Towne Centre Dr San Diego, CA - 92122